Continuous Glucose Monitoring in Pregnancy: What the Evidence Actually Shows for Gestational Diabetes

Gestational diabetes mellitus (GDM)—high blood sugar that develops during pregnancy—is becoming more common as obesity and type 2 diabetes rates rise. It carries real risks for both mother and baby, including increased chances of the child developing type 2 diabetes later in life.

Managing gestational diabetes typically involves dietary changes, physical activity, and regular blood sugar monitoring. Continuous glucose monitoring has already transformed care for pregnant women with type 1 diabetes by tracking blood sugar patterns throughout the day and night. This success has led many to wonder: could CGM also improve outcomes for women with gestational diabetes?

CGM devices offer advantages over traditional finger-stick testing. They capture blood sugar spikes after meals, show how much blood sugar varies throughout the day, and reveal how much time glucose stays in a healthy range. In theory, this detailed picture could help women and their doctors fine-tune management plans.

However, theory and practice don't always align. Several large randomized controlled trials—the gold standard for medical evidence—have produced conflicting results. Some studies found modest improvements in blood sugar measurements, but others found no clear benefit for important outcomes like maternal health or newborn health.

One major problem is that experts haven't agreed on what blood sugar targets should be for gestational diabetes when using CGM. Current clinical guidelines don't offer clear direction beyond recommending the same targets used for traditional blood sugar testing. Without clear targets, it's hard for doctors and patients to know what CGM data actually means or how to act on it.

The conflicting trial results, combined with the lack of established targets, leave important questions unanswered: Does CGM actually lead to better outcomes for mothers and babies? Is the cost justified? Does it work better for some women than others?

Researchers emphasize that closing these gaps requires large, well-designed studies that include diverse populations. They also highlight the need for individual participant data meta-analyses—a rigorous approach where researchers pool detailed information from multiple studies to identify patterns that individual trials might miss.

For now, the role of CGM in gestational diabetes management remains uncertain. Women with gestational diabetes should discuss their individual options with their care team, who can weigh the potential benefits and limitations based on the latest evidence.

Source: BMC medicine. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.